Remote Ischaemic Conditioning (RIC) in Heart Failure
Launched by UNIVERSITY OF LEICESTER · Sep 23, 2024
Trial Information
Current as of May 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a treatment called remote ischaemic conditioning (RIC) combined with exercise to see how it affects blood flow to the heart in people with heart failure or those at risk for it. Heart failure with preserved ejection fraction (HFpEF) means that the heart is not pumping blood effectively, even though the heart's pumping ability (ejection fraction) is normal. The study is looking for participants aged 18 and older, who have been diagnosed with HFpEF, stable type 2 diabetes, or dilated cardiomyopathy, which is a condition that affects the heart's ability to pump blood.
If you join the trial, you will be monitored closely to see how this treatment affects your heart and overall health. It's important to note that certain conditions, like severe heart valve disease or certain types of heart blockages, may prevent you from participating. This study is currently recruiting participants, and it aims to help improve treatments for heart failure, potentially benefiting many patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>18 years
- • Ability to provide written consent
- • clinical diagnosis of HFpEF (LVEF ≥50%; symptoms and signs of heart failure \[HF\] caused by a structural and/or functional abnormality, and at least one: elevated natriuretic peptides; ambulatory; BNP ≥35 pg/mL or NT-proBNP ≥125 pg/mL or hospitalised; BNP ≥100 pg/mL or NT-proBNP ≥300 pg/mL, and objective evidence of cardiogenic pulmonary or systemic congestion) OR stable type 2 diabetes (determined by formal diagnosis in hospital or GP case records with diagnostic oral glucose tolerance test or glycated haemoglobin level ≥6.5%) and with ACC/AHA stage B HF (structural disorder of the heart but no current or previous symptoms of HF) OR confirmed diagnosis of dilated cardiomyopathy
- Exclusion Criteria:
- • Absolute contraindications to MRI or contrast (e.g. severe claustrophobia, pregnancy, ferromagnetic implants, inability to lie flat, severe renal impairment eGFR\<30ml/min/m2)
- • Moderate to severe valvular heart disease
- • Confirmed coronary artery disease (\>50% narrowing in any major epicardial coronary artery on invasive or computed tomography coronary angiography, previous myocardial infarction, previous percutaneous intervention or coronary bypass surgery)
- • Known arterial stenosis of the upper extremity
About University Of Leicester
The University of Leicester is a leading research institution in the UK, renowned for its commitment to advancing scientific knowledge and improving healthcare through innovative clinical trials. The university fosters a collaborative environment that integrates diverse disciplines, enabling the development of cutting-edge research initiatives aimed at addressing pressing medical challenges. With a focus on ethical practices and patient-centered outcomes, the University of Leicester is dedicated to enhancing clinical research methodologies and contributing to the advancement of medical sciences, ultimately striving to translate research findings into tangible health benefits for communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leicester, Leics, United Kingdom
Patients applied
Trial Officials
Jayanth R Arnold, BMBCh DPhil
Principal Investigator
University of Leicester
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported